Hartland & Co. LLC cut its stake in shares of Baxter International Inc. (NYSE:BAX) by 3.9% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 19,318 shares of the medical instruments supplier’s stock after selling 786 shares during the period. Hartland & Co. LLC’s holdings in Baxter International were worth $1,002,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in BAX. Legal & General Group Plc increased its stake in shares of Baxter International by 7.7% in the first quarter. Legal & General Group Plc now owns 2,979,527 shares of the medical instruments supplier’s stock valued at $154,518,000 after buying an additional 213,357 shares in the last quarter. Good Life Advisors LLC increased its stake in shares of Baxter International by 21.6% in the first quarter. Good Life Advisors LLC now owns 5,266 shares of the medical instruments supplier’s stock valued at $279,000 after buying an additional 935 shares in the last quarter. Laurion Capital Management LP increased its stake in shares of Baxter International by 19,847.7% in the first quarter. Laurion Capital Management LP now owns 770,159 shares of the medical instruments supplier’s stock valued at $39,941,000 after buying an additional 774,059 shares in the last quarter. Sector Gamma AS increased its stake in shares of Baxter International by 8.8% in the first quarter. Sector Gamma AS now owns 1,036,233 shares of the medical instruments supplier’s stock valued at $53,739,000 after buying an additional 83,400 shares in the last quarter. Finally, WINTON GROUP Ltd increased its stake in shares of Baxter International by 68.0% in the first quarter. WINTON GROUP Ltd now owns 711,120 shares of the medical instruments supplier’s stock valued at $33,849,000 after buying an additional 287,926 shares in the last quarter. 84.21% of the stock is currently owned by institutional investors and hedge funds.

Baxter International Inc. (BAX) traded up 0.49% on Friday, reaching $59.88. 1,594,201 shares of the company’s stock were exchanged. Baxter International Inc. has a one year low of $43.13 and a one year high of $63.14. The firm has a 50 day moving average of $60.72 and a 200-day moving average of $54.77. The stock has a market cap of $32.55 billion, a price-to-earnings ratio of 36.33 and a beta of 0.66.

Baxter International (NYSE:BAX) last issued its quarterly earnings results on Wednesday, July 26th. The medical instruments supplier reported $0.63 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.57 by $0.06. The company had revenue of $2.61 billion for the quarter, compared to analyst estimates of $2.59 billion. Baxter International had a net margin of 8.85% and a return on equity of 15.09%. The business’s revenue for the quarter was up .8% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.46 earnings per share. Equities research analysts forecast that Baxter International Inc. will post $2.39 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Monday, October 2nd. Shareholders of record on Friday, September 1st will be paid a dividend of $0.16 per share. The ex-dividend date is Wednesday, August 30th. This represents a $0.64 dividend on an annualized basis and a yield of 1.07%. Baxter International’s dividend payout ratio (DPR) is presently 38.79%.

ILLEGAL ACTIVITY WARNING: “Baxter International Inc. (NYSE:BAX) Position Reduced by Hartland & Co. LLC” was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/08/04/hartland-co-llc-sells-786-shares-of-baxter-international-inc-nysebax-updated-updated-updated.html.

Several equities research analysts have recently weighed in on the stock. Zacks Investment Research downgraded shares of Baxter International from a “buy” rating to a “hold” rating in a research note on Tuesday. BidaskClub downgraded shares of Baxter International from a “strong-buy” rating to a “buy” rating in a research note on Monday. UBS AG raised their price target on shares of Baxter International from $57.00 to $62.00 and gave the stock a “neutral” rating in a research note on Friday, July 28th. Leerink Swann reaffirmed an “outperform” rating and issued a $75.00 price target (up previously from $67.00) on shares of Baxter International in a research note on Thursday, July 27th. Finally, Cowen and Company reaffirmed a “market perform” rating and issued a $68.00 price target (up previously from $66.00) on shares of Baxter International in a research note on Thursday, July 27th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. Baxter International has an average rating of “Buy” and a consensus target price of $65.33.

In related news, SVP Brik V. Eyre sold 130,732 shares of the company’s stock in a transaction that occurred on Monday, May 8th. The shares were sold at an average price of $55.69, for a total transaction of $7,280,465.08. Following the sale, the senior vice president now directly owns 49,966 shares in the company, valued at $2,782,606.54. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Carole J. Shapazian sold 2,618 shares of the company’s stock in a transaction that occurred on Tuesday, May 23rd. The stock was sold at an average price of $57.92, for a total transaction of $151,634.56. Following the sale, the director now owns 9,848 shares in the company, valued at $570,396.16. The disclosure for this sale can be found here. Insiders have sold 137,110 shares of company stock worth $7,642,246 over the last quarter. Insiders own 0.05% of the company’s stock.

About Baxter International

Baxter International Inc, through its subsidiaries, provides renal and hospital products. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures sterile intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics and biosurgery products.

Institutional Ownership by Quarter for Baxter International (NYSE:BAX)

Receive News & Stock Ratings for Baxter International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International Inc. and related stocks with our FREE daily email newsletter.